CDISC SDTM Controlled Terminology, 2014-06-27

Total Page:16

File Type:pdf, Size:1020Kb

CDISC SDTM Controlled Terminology, 2014-06-27 CDISC SDTM Controlled Terminology, 2014-06-27 Source: NCI EVS Terminology Resources website: http://www.cancer.gov/cancertopics/cancerlibrary/terminologyresources/cdisc NCI CDISC Submission Codelist Name CDISC Definition Codelist Code Value Extensible C66767 ACN Action Taken with Terminology specifying changes to the study treatment as a result of an No Study Treatment adverse event. C101865 ACSPCAT Acute Coronary A classification of the presentation of acute coronary syndrome. No Syndrome Presentation Category C66769 AESEV Severity/Intensity A scale that defines the degree or state of disease existing in a patient as a No Scale for Adverse result of the occurrence of an adverse event. (NCI) Events C66781 AGEU Age Unit Those units of time that are routinely used to express the age of a subject. No C101842 CACRDSC Canadian The anginal classifications as measured by the Canadian Cardiovascular No Cardiovascular Society grading scale. Society Classification C101843 CADPRSN Coronary Artery A terminology codelist associated with coronary artery disease No Disease Presentation presentation. C101849 CADRISK Coronary Artery A terminology codelist to describe the relative risk of coronary artery No Disease Risk disease. C101844 CADSYMP Coronary Artery A terminology codelist that contains symptoms associated with coronary No Disease Symptoms artery disease. C101860 CARTDOM Coronary Artery A codelist to describe whether the posterior descending artery comes from No Dominance the right or left vessel system. C102575 CCINVTYP Contact Case Terminology relevant to the identification and clinical investigation of Yes Investigation Contact disease contacts. Type C101837 CCRCLS Consensus Cardiac Classification system test name for cardiac parameters that are authored or Yes Classification System endorsed by organizations. Test Name C101838 CCRCLSCD Consensus Cardiac Classification system test code for cardiac parameters that are authored or Yes Classification System endorsed by organizations. Test Code C66786 COUNTRY Country A collective generic term that refers here to a wide variety of No dependencies, areas of special sovereignty, uninhabited islands, and other entities in addition to the traditional countries or independent states. (NCI) C101866 CRYDFMAN Cardiac Rhythm The effect that a cardiac rhythm device malfunction had on the ability to Yes Device Failure stimulate the heart. Manifestation C101864 CSLVLNIM Reason CS/LV Lead The reason that a Coronary Sinus Access or Left Ventricular (CS/LV) lead No Not Implanted was not implanted. C101846 CVEXAM Cardiovascular Test A terminology codelist to describe the findings test name from a cardiac Yes Name examination. C101847 CVEXAMCD Cardiovascular Test A terminology codelist to describe the findings test code from a cardiac Yes Code examination. C101854 CVLSTSEV Cardiac Valvular A terminology codelist to describe the severity of cardiac valvular stenosis. No Stenosis Severity C101853 CVLVRSEV Cardiac Valvular A terminology codelist to describe the severity of cardiac valvular No Regurgitation Severity regurgitation. C101859 CVPRCIND Cardiac Procedure The reason that a subject had a cardiac procedure. Yes Indication C101850 CVSLDEXT Coronary Vessel A terminology codelist to describe the extent of coronary artery disease. No Disease Extent C78731 DATEST Drug Accountability The name of the test for the drug accountability assessment. Yes Test Name C78732 DATESTCD Drug Accountability The short name, or code, of the test for the drug accountability Yes Test Code assessment. C116107 DDTEST Death Details Test Terminology relevant to the death detail assessment name. Yes Name page 1 of 577 NCI CDISC Submission Codelist Name CDISC Definition Codelist Code Value Extensible C116108 DDTESTCD Death Details Test Terminology relevant to the death detail assessment short name. Yes Code C111110 DEACNDEV Device Events Action A terminology codelist based on the action taken with respect to the Yes Taken with Device device. C111109 DECAT Device Events A terminology codelist based on the category of related records for the Yes Category device event. C101857 DIABTHPY Diabetes Therapy A terminology codelist that describes the treatment method for diabetes. Yes C66788 DICTNAM Dictionary Name A name given to a reference source that lists words and gives their Yes meaning. (NCI) C106480 DIPARM Device Identifier Long A terminology codelist for the long name of the identifier characteristic of Yes Name the device. C106481 DIPARMCD Device Identifier A terminology codelist for the short name of the identifier characteristic of Yes Short Name the device. C99074 DIR Directionality CDISC terminology for anatomical location or specimen further detailing Yes directionality. C101863 DISCHDX Discharge Disposition The destination or circumstance at the time of discharge. Yes C102576 DOBSTLOC Directly Observed Terminology relevant to the physical location at which the medication or No Therapy Location therapy was observed, by the healthcare provider, as being taken by the subject. C66734 DOMAIN SDTM Domain A unique, 2-character domain code used in the regulatory submission Yes Abbreviation process. The domain abbreviation is used consistently throughout the submission, i.e. in the dataset name, as the value of the domain variable within the dataset, and as a prefix for most variable names in the dataset. (CDISC Glossary) C111112 DOTEST Device Properties Test A terminology codelist based on the test name used to obtain the device Yes Name property. C111111 DOTESTCD Device Properties Test A terminology codelist based on the test code used to obtain the device Yes Code property. C102577 DRSTAT Drug Resistance Terminology relevant to the state or condition of the microbe or lesion to Yes Status indicate whether it is resistant to drugs normally used in treatment. C74558 DSCAT Category for Classifications that describe and group pertinent events that occur Yes Disposition Event throughout the conduct of a clinical trial. C102578 DSSOUT Disease Outcome Terminology relevant to the measurable result or effect of treatment on a Yes disease. C112037 DTDECOD Device Tracking and A terminology codelist based on the verbatim or preprinted term for the Yes Disposition Event device tracking and disposition event that occurs. Dictionary Derived Term C106482 DUTEST Device-In-Use Test A terminology codelist for the test name of the test or examination used to Yes Name obtain the measurement or finding of the device in use. C106483 DUTESTCD Device-In-Use Test A terminology codelist for the test code of the test or examination used to Yes Code obtain the measurement or finding of the device in use. C90013 EGLEAD ECG Lead Terminology related to electrocardiogram lead names. Yes C71151 EGMETHOD ECG Test Method Terminology codelist used with ECG Test Methods within CDISC. Yes C71150 EGSTRESC ECG Result Terminology codelist used with ECG Findings and Abnormalities within Yes CDISC. C71152 EGTEST ECG Test Name Terminology codelist used with ECG Test Names within CDISC. Yes C71153 EGTESTCD ECG Test Code Terminology codelist used with ECG Tests within CDISC. Yes C111108 EMPSTAT Employment Status Terminology relevant to the state of being engaged in an activity or service Yes for wages or salary. C99079 EPOCH Epoch The name of the EPOCH. Yes C66790 ETHNIC Ethnic Group A social group characterized by a distinctive social and cultural tradition No maintained from generation to generation, a common history and origin and a sense of identification with the group; members of the group have distinctive features in their way of life, shared experiences and often a common genetic heritage; these features may be reflected in their experience of health and disease. (NCI) page 2 of 577 NCI CDISC Submission Codelist Name CDISC Definition Codelist Code Value Extensible C78735 EVAL Evaluator The role that the individual or entity plays with respect to a specific Yes situation or person. C102579 EVDRETRT Supporting Evidence Terminology relevant to the clinical evidence to support reason for re- Yes for Re-Treatment treatment of disease. C101833 FATEST Findings About Test Terminology relevant to the test names that describe findings about an Yes Name event or intervention. C101832 FATESTCD Findings About Test Terminology relevant to the test codes that describe findings about an Yes Code event or intervention. C71113 FREQ Frequency The terminology that includes terms pertaining to frequency within CDISC. Yes C66726 FRM Pharmaceutical The form of the completed pharmaceutical product, e.g. tablet, capsule, Yes Dosage Form injection, elixir, suppository. Dosage form can have a significant effect on the onset, duration and intensity of the pharmacological action of a drug. A pharmaceutical dosage form controls the rate at which the drug is released into the biological fluids. This release rate affects its intrinsic absorption pattern and therefore, the bioavailability of the drug. C111114 GENSMP Genetic Sample Type Terminology relevant to the type of nucleic acid which was derived from Yes the collected sample. C103329 GNRLOBSC General Observation Terminology related to the classification of a CDISC domain. No Class C101851 GRSTNLOC Location of Most Terminology used to describe the part of the graft that is most severely No Severe Stenosis stenotic. Within a Graft C66797 IECAT Category for A collection of criteria on which subjects are evaluated and that must be No Inclusion/Exclusion met by all study subjects. (NCI) C99076 INTMODEL Intervention Model The trial design developed
Recommended publications
  • B1–Proteases As Molecular Targets of Drug Development
    Abstracts B1–Proteases as Molecular Targets of Drug Development B1-001 lin release from the beta cells. Furthermore, GLP-1 also stimu- DPP-IV structure and inhibitor design lates beta cell growth and insulin biosynthesis, inhibits glucagon H. B. Rasmussen1, S. Branner1, N. Wagtmann3, J. R. Bjelke1 and secretion, reduces free fatty acids and delays gastric emptying. A. B. Kanstrup2 GLP-1 has therefore been suggested as a potentially new treat- 1Protein Engineering, Novo Nordisk A/S, Bagsvaerd, Denmark, ment for type 2 diabetes. However, GLP-1 is very rapidly degra- 2Medicinal Chemistry, Novo Nordisk A/S, Maaloev, Denmark, ded in the bloodstream by the enzyme dipeptidyl peptidase IV 3Discovery Biology, Novo Nordisk A/S, Maaloev, DENMARK. (DPP-IV; EC 3.4.14.5). A very promising approach to harvest E-mail: [email protected] the beneficial effect of GLP-1 in the treatment of diabetes is to inhibit the DPP-IV enzyme, thereby enhancing the levels of The incretin hormones GLP-1 and GIP are released from the gut endogenously intact circulating GLP-1. The three dimensional during meals, and serve as enhancers of glucose stimulated insu- structure of human DPP-IV in complex with various inhibitors 138 Abstracts creates a better understanding of the specificity and selectivity of drug-like transition-state inhibitors but can be utilized for the this enzyme and allows for further exploration and design of new design of non-transition-state inhibitors that compete for sub- therapeutic inhibitors. The majority of the currently known DPP- strate binding. Besides carrying out proteolytic activity, the IV inhibitors consist of an alpha amino acid pyrrolidine core, to ectodomain of memapsin 2 also interacts with APP leading to which substituents have been added to optimize affinity, potency, the endocytosis of both proteins into the endosomes where APP enzyme selectivity, oral bioavailability, and duration of action.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Final Program
    In Memoriam: Final Program XXV Congress of the International Society on Thrombosis and Haemostasis and 61st Annual SSC Meeting June 20 – 25, 2015 Toronto, Canada www.isth2015.org 1 Final Program Table of Contents 3 Venue and Contacts 5 Invitation and Welcome Message 12 ISTH 2015 Committees 24 Congress Support 25 Sponsors and Exhibitors 27 ISTH Awards 32 ISTH Society Information 37 Program Overview 41 Program Day by Day 55 SSC and Educational Program 83 Master Classes and Career Mentorship Sessions 87 Nurses Forum 93 Scientific Program, Monday, June 22 94 Oral Communications 1 102 Plenary Lecture 103 State of the Art Lectures 105 Oral Communications 2 112 Abstract Symposia 120 Poster Session 189 Scientific Program, Tuesday, June 23 190 Oral Communications 3 198 Plenary Lecture 198 State of the Art Lectures 200 Oral Communications 4 208 Plenary Lecture 209 Abstract Symposia 216 Poster Session 285 Scientific Program, Wednesday, June 24 286 Oral Communications 5 294 Plenary Lecture 294 State of the Art Lectures 296 Oral Communications 6 304 Abstract Symposia 311 Poster Session 381 Scientific Program, Thursday, June 25 382 Oral Communications 7 390 Plenary Lecture 390 Abstract Symposia 397 Highlights of ISTH 399 Exhibition Floor Plan 402 Exhibitor List 405 Congress Information 406 Venue Plan 407 Congress Information 417 Social Program 418 Toronto & Canada Information 421 Transportation in Toronto 423 Future ISTH Meetings and Congresses 2 427 Authors Index 1 Thank You to Everyone Who Supported the Venue and Contacts 2014 World Thrombosis Day
    [Show full text]
  • Center for Drug Evaluation and Research Application
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 22-512 PHARMACOLOGY REVIEW(S) Tertiary Pharmacology Review By: Paul C. Brown, Ph.D., ODE Associate Director for Pharmacology and Toxicology OND IO NDA: 22-307 Submission date: 4/19/2010 Drug: Pradaxa™ (Dabigatran etexilate mesylate) Sponsor: Boehringer Ingelheim Pharma GmbH & Co. KG Indication: Prevention of stroke and systemic embolism in patients with atrial fibrillation Reviewing Division: Division of Cardiovascular and Renal Products Comments: The pharm/tox reviewer and supervisor found the nonclinical information submitted for dabigatran to be sufficient to support the proposed use. The reviewer proposes pregnancy category C for the labeling. Dabigatran induced some reproductive toxicity in rats manifest as a decreased number of implantations, decreased number of viable fetuses, increase in the resorption rate, increase in post-implantation loss, and an increase in the number of dead offspring when given at doses of 70 mg/kg (about 2.6 to 3 times the MRHD of 300 mg/day on a mg/m2 basis). Dabigatran also induced some fetal structural variations but did not induce fetal malformations in rats or rabbits. Dabigatran was evaluated for carcinogenicity in 2-year rat and mouse studies. The Executive Carcinogenicity Assessment Committee concluded that these studies were adequate and there were no drug-related tumors in either study. Conclusions: I concur with the Division pharm/tox conclusion that the nonclinical data support approval of this NDA. No additional nonclinical studies are recommended at this time. The proposed Established Pharmacologic Class for dabigatran is "direct thrombin inhibitor". This is appropriate because it is consistent with other moieties of this class.
    [Show full text]
  • Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases
    Handbook of Proteolytic Enzymes Second Edition Volume 1 Aspartic and Metallo Peptidases Alan J. Barrett Neil D. Rawlings J. Fred Woessner Editor biographies xxi Contributors xxiii Preface xxxi Introduction ' Abbreviations xxxvii ASPARTIC PEPTIDASES Introduction 1 Aspartic peptidases and their clans 3 2 Catalytic pathway of aspartic peptidases 12 Clan AA Family Al 3 Pepsin A 19 4 Pepsin B 28 5 Chymosin 29 6 Cathepsin E 33 7 Gastricsin 38 8 Cathepsin D 43 9 Napsin A 52 10 Renin 54 11 Mouse submandibular renin 62 12 Memapsin 1 64 13 Memapsin 2 66 14 Plasmepsins 70 15 Plasmepsin II 73 16 Tick heme-binding aspartic proteinase 76 17 Phytepsin 77 18 Nepenthesin 85 19 Saccharopepsin 87 20 Neurosporapepsin 90 21 Acrocylindropepsin 9 1 22 Aspergillopepsin I 92 23 Penicillopepsin 99 24 Endothiapepsin 104 25 Rhizopuspepsin 108 26 Mucorpepsin 11 1 27 Polyporopepsin 113 28 Candidapepsin 115 29 Candiparapsin 120 30 Canditropsin 123 31 Syncephapepsin 125 32 Barrierpepsin 126 33 Yapsin 1 128 34 Yapsin 2 132 35 Yapsin A 133 36 Pregnancy-associated glycoproteins 135 37 Pepsin F 137 38 Rhodotorulapepsin 139 39 Cladosporopepsin 140 40 Pycnoporopepsin 141 Family A2 and others 41 Human immunodeficiency virus 1 retropepsin 144 42 Human immunodeficiency virus 2 retropepsin 154 43 Simian immunodeficiency virus retropepsin 158 44 Equine infectious anemia virus retropepsin 160 45 Rous sarcoma virus retropepsin and avian myeloblastosis virus retropepsin 163 46 Human T-cell leukemia virus type I (HTLV-I) retropepsin 166 47 Bovine leukemia virus retropepsin 169 48
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan Et Al
    US 2004.008 1648A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan et al. (43) Pub. Date: Apr. 29, 2004 (54) ADZYMES AND USES THEREOF Publication Classification (76) Inventors: Noubar B. Afeyan, Lexington, MA (51) Int. Cl." ............................. A61K 38/48; C12N 9/64 (US); Frank D. Lee, Chestnut Hill, MA (52) U.S. Cl. ......................................... 424/94.63; 435/226 (US); Gordon G. Wong, Brookline, MA (US); Ruchira Das Gupta, Auburndale, MA (US); Brian Baynes, (57) ABSTRACT Somerville, MA (US) Disclosed is a family of novel protein constructs, useful as Correspondence Address: drugs and for other purposes, termed “adzymes, comprising ROPES & GRAY LLP an address moiety and a catalytic domain. In Some types of disclosed adzymes, the address binds with a binding site on ONE INTERNATIONAL PLACE or in functional proximity to a targeted biomolecule, e.g., an BOSTON, MA 02110-2624 (US) extracellular targeted biomolecule, and is disposed adjacent (21) Appl. No.: 10/650,592 the catalytic domain So that its affinity Serves to confer a new Specificity to the catalytic domain by increasing the effective (22) Filed: Aug. 27, 2003 local concentration of the target in the vicinity of the catalytic domain. The present invention also provides phar Related U.S. Application Data maceutical compositions comprising these adzymes, meth ods of making adzymes, DNA's encoding adzymes or parts (60) Provisional application No. 60/406,517, filed on Aug. thereof, and methods of using adzymes, Such as for treating 27, 2002. Provisional application No. 60/423,754, human Subjects Suffering from a disease, Such as a disease filed on Nov.
    [Show full text]
  • Part 7. Indexes
    Peptide Sequences Index Part 7. Indexes Index A. Peptide Sequences White & White - Proteins, Peptides & Amino Acids SourceBook 975 Peptide Sequences Index Ala-Ala-Pro-Lys . 218 A Ala-Ala-Pro-Met . 218 Ala-Ala-Pro-Nle . 218 Abu-Ala· 208 Ala-Ala-Pro-Nva . 218 Abu-Arg . 208, 740 Ala-Ala-Pro-Orn • 218 Abu-Asn-Arg-Leu-Glu-Ala-Ser-Ser-Arg-Ser-Ser-Lys . 208 Ala-Ala-Pro-Phe . 209, 218, 219, 385 Abu-Gly . 208, 369 Ala-Ala-Pro-Val . 217, 219, 220 Abu-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr· 208 Ala-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr . 220 Abu-Ser-Gln-Asn-Tyr-Pro-lie-Val-Gin· 208 Ala-Ala-Trp-Phe-Lys· 220 Abz-Ala-Ala-Phe-Phe . 208 Ala-Ala-Trp-Phe-Pro-pro-Nle . 220 Abz-Ala-Arg-Val-Nle-Phe-Glu-Ala-Nle . 208 Ala-Ala-Tyr . 221 Abz-Ala-Gly-Leu-Ala . 208 Ala-Ala-Tyr-Ala . 221 Abz-Ala-Phe-Ala-Phe-Asp-Val-Phe-Tyr-Asp . 209 Ala-Ala-Tyr-Ala-Ala . 221 Abz-Arg-Val-Lys-Arg-Gly-Leu-Ala-Tyr-Asp . 209 Ala-Ala-Val· 221, 222 Abz-Arg-Val-Nle-Phe-Glu-Ala-Nle . 209 Ala-Ala-Val-Ala • 221, 222 Abz-Gln-Val-Val-Ala-Gly-Ala . 209 Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu- Abz-Glu-Thr-Leu-Phe-Gln-Gly-Pro-Val-Phe . 209 Ala-Pro-Asp-Glu-Val-Asp . 221 Abz-Gly . 209, 385 Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu­ Abz-Gly-Ala-Ala-Pro-Phe-Tyr-Asp .
    [Show full text]
  • 66Th Annual ISTH 2020 SSC Virtual Sessions Minutes
    66th Annual ISTH 2020 SSC Virtual Sessions Minutes Subcommittees Biorheology .................................................................................................. 3 Control of Anticoagulation ............................................................................ 6 Disseminated Intravascular Coagulation ...................................................... 10 Factor VIII, Factor IX and Rare Coagulation Disorders ................................ 12 Factor XIII and Fibrinogen ............................................................................ 14 Fibrinolysis ................................................................................................... 18 Genomics in Thrombosis and Hemostasis ................................................... 22 Hemostasis and Malignancy ........................................................................ 25 Lupus Anticoagulant/Phospholipid Dependent Antibodies ........................... 29 Models of Thrombosis and Hemostasis ....................................................... 34 Pediatric and Neonatal Hemostasis and Thrombosis ................................... 39 Perioperative and Critical Care Thrombosis and Hemostasis ...................... 43 Plasma Coagulation Inhibitors ...................................................................... 45 Platelet Immunology ..................................................................................... 53 Platelet Physiology………………………………………………………….…… 56 Predictive and Diagnostic Variables in Thrombotic Disease
    [Show full text]
  • Proteomics and Antivenomics of Echis Carinatus Carinatusvenom
    www.nature.com/scientificreports OPEN Proteomics and antivenomics of Echis carinatus carinatus venom: Correlation with pharmacological Received: 13 February 2017 Accepted: 30 October 2017 properties and pathophysiology of Published: xx xx xxxx envenomation Aparup Patra, Bhargab Kalita, Abhishek Chanda & Ashis K. Mukherjee The proteome composition of Echis carinatus carinatus venom (ECV) from India was studied for the frst time by tandem mass spectrometry analysis. A total of 90, 47, and 22 distinct enzymatic and non- enzymatic proteins belonging to 15, 10, and 6 snake venom protein families were identifed in ECV by searching the ESI-LC-MS/MS data against non-redundant protein databases of Viperidae (taxid 8689), Echis (taxid 8699) and Echis carinatus (taxid 40353), respectively. However, analysis of MS/MS data against the Transcriptome Shotgun Assembly sequences (87 entries) of conger E. coloratus identifed only 14 proteins in ECV. Snake venom metalloproteases and snaclecs, the most abundant enzymatic and non-enzymatic proteins, respectively in ECV account for defbrinogenation and the strong in vitro pro-coagulant activity. Further, glutaminyl cyclase, aspartic protease, aminopeptidase, phospholipase B, vascular endothelial growth factor, and nerve growth factor were reported for the frst time in ECV. The proteome composition of ECV was well correlated with its biochemical and pharmacological properties and clinical manifestations observed in Echis envenomed patients. Neutralization of enzymes and pharmacological properties of ECV, and immuno-cross-reactivity studies unequivocally point to the poor recognition of <20 kDa ECV proteins, such as PLA2, subunits of snaclec, and disintegrin by commercial polyvalent antivenom. According to the World Health Organization, snakebite is a major health challenge in tropical and sub-tropical countries including India, and therefore, it is considered as a neglected tropical disease1.
    [Show full text]
  • Proteomic Characterization and Comparison of Malaysian Tropidolaemus Wagleri and Cryptelytrops Purpureomaculatus Venom Using Shotgun-Proteomics
    toxins Article Proteomic Characterization and Comparison of Malaysian Tropidolaemus wagleri and Cryptelytrops purpureomaculatus Venom Using Shotgun-Proteomics Syafiq Asnawi Zainal Abidin 1, Pathmanathan Rajadurai 1,2, Md Ezharul Hoque Chowdhury 1, Muhamad Rusdi Ahmad Rusmili 3, Iekhsan Othman 1,* and Rakesh Naidu 1 1 Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Selangor Darul Ehsan 47500, Malaysia; [email protected] (S.A.Z.A.); [email protected] (P.R.); [email protected] (M.E.H.C.); [email protected] (R.N.) 2 Ramsay Sime Darby Healthcare, Sime Darby Medical Centre, No. 1, Jalan SS12/1A, Subang Jaya, Selangor Darul Ehsan 47500, Malaysia 3 Kuliyyah of Pharmacy, International Islamic University Malaysia, Kuantan Campus, Bandar Indera Mahkota, Kuantan, Pahang Darul Makmur 25200, Malaysia; [email protected] * Correspondence: [email protected]; Tel.: +60-3-5514-6332 Academic Editor: Bryan Grieg Fry Received: 19 May 2016; Accepted: 11 October 2016; Published: 18 October 2016 Abstract: Tropidolaemus wagleri and Cryptelytrops purpureomaculatus are venomous pit viper species commonly found in Malaysia. Tandem mass spectrometry analysis of the crude venoms has detected different proteins in T. wagleri and C. purpureomaculatus. They were classified into 13 venom protein families consisting of enzymatic and nonenzymatic proteins. Enzymatic families detected in T. wagleri and C. purpureomaculatus venom were snake venom metalloproteinase, phospholipase 0 A2, L-amino acid oxidase, serine proteases, 5 -nucleotidase, phosphodiesterase, and phospholipase B. In addition, glutaminyl cyclotransferase was detected in C. purpureomaculatus. C-type lectin-like proteins were common nonenzymatic components in both species.
    [Show full text]
  • Protease Activity As a Prognostic Factor for Wound Healing in Venous Leg Ulcers (Review)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Keele Research Repository Cochrane Library Cochrane Database of Systematic Reviews Protease activity as a prognostic factor for wound healing in venous leg ulcers (Review) Westby MJ, Dumville JC, Stubbs N, Norman G, Wong JKF, Cullum N, Riley RD Westby MJ, Dumville JC, Stubbs N, Norman G, Wong JKF, Cullum N, Riley RD. Protease activity as a prognostic factor for wound healing in venous leg ulcers. Cochrane Database of Systematic Reviews 2018, Issue 9. Art. No.: CD012841. DOI: 10.1002/14651858.CD012841.pub2. www.cochranelibrary.com Protease activity as a prognostic factor for wound healing in venous leg ulcers (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Cochrane Trusted evidence. Informed decisions. Library Better health. Cochrane Database of Systematic Reviews T A B L E O F C O N T E N T S HEADER......................................................................................................................................................................................................... 1 ABSTRACT..................................................................................................................................................................................................... 1 PLAIN LANGUAGE SUMMARY....................................................................................................................................................................... 2 BACKGROUND.............................................................................................................................................................................................
    [Show full text]
  • Part 2. Proteins
    Proteins Part 2. Proteins White & White — Proteins, Peptides & Amino Acids SourceBook 5 Proteins 4-IBBL Acid Glycoprotein VI, α1- PeproTech 310-11 Human recombinant, expressed in E. coli Synonyms: Orosomucoid MW 19.5k >98% (SDS-PAGE) & HPLC; <0.1 ng endotoxin per Fluka 50646 Human plasma MW 45k ≥98% (GE); 60% mg (1EU/mg); lyophilized | Member of the emerging family of protein; 6% water | Arnaud, P et al, Meth Enzymol, 163: 418, ligands with structural homology to tumor necrosis factor; 185 AA; 1988; Eap, CB & Baumann, P, Electrophoresis, 9: 650, 1988 ED50 < 10ng/mL; SA determined by the dose-dependent stimulation of IL-8 production by human PBMC Acid Glycoprotein, α1- α 6CKINE Synonyms: Orosomucoid; Seromucoid, 1- Synonyms: Exodus II; SLC; T-Cell Activation Gene IV Fluka 50647 Bovine serum ≥99% (gel electrophoresis); ≤5% Biodesign A52013M E. coli Purified | Species specificity: water; ~70% protein mouse Biodesign A50106H Human Purified Biodesign A52035H E. coli Purified Fitzgerald 30-AA01 Human plasma High purity | Chemicon GF086 Human ≥95% Orosomucoid ICN 153905 Human plasma MW 44.1k Lyophilized, salt Biogenesis 4396-0150 Human r-DNA Lyophilized free, >99% BioSource International PHC1474 Human recombinant ICN 191348 Human plasma MW 44.1k Lyophilized, salt PeproTech 300-35 Human recombinant, expressed in E. coli free, >99% (SDS-PAGE) | Negative for HBs Ag & HIV antibodies; MW 12.2k >98% (SDS-PAGE) & HPLC; <0.1 ng endotoxin per Schmid, K etal, Biochemistry, 12:2711, 1973 mg (1EU/mg); lyophilized | In the CC chemokine family; similar to Scipac P153-0 Orosomucoid, from serum/plasma >99%; Exodus-1 (aka MIP-3α & LARC); inhibits hemopoiesis & stimulating lyophilized | Acute phase serum protein chemotaxis; 111 AA; SA determined by its ability to chemoattract total lymphocyte population Scipac P153-1 Orosomucoid, from serum/plasma >96%; lyophilized | Acute phase serum protein Sigma C 0720 Human recombinant, expressed in E.
    [Show full text]